GUÍA MANEJO ANTIRRETROVIRAL PERSONAS VIH

BIBLIOGRAFÍA
Capítulo 1
1. Secretaría de Salud. Norma Oficial Mexicana NOM-010-SSA2-
2010, para la prevención y control de la infección por virus de la
inmunodeficiencia humana. Disponible en:
http://www.salud.gob.mx/unidades/cdi/nom/010ssa23.html
Acceso (27-02-2008).
2. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-
Infected Adults and Adolescents. Nov 2013. Disponible en
http://aidsinfo.nih.gov/guidelines
3. European AIDS Clinical Society. Guidelines for treatment of HIVinfected
adults in Europe. Versión 7.0 Oct 2013. Disponible en
http://www.eacsociety.org/Guidelines.aspx
4. Grupo de Estudio del SIDA-SEIMC. Documento de consenso de
GESIDA/Plan Nacional sobre el Sida respecto al tratamiento
antirretroviral en adultos infectados por el virus de la
inmunodeficiencia humana. Enero 2014. Disponible en
http://www.gesida-
seimc.org/contenidos/guiasclinicas/2014/gesida-guiasclinicas-
2014-tar.pdf
5. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS,
Horberg MA. Primary care guidelines for the management of
persons infected with human immunodeficiency virus: 2013
update by the HIV Medicine Association of the Infectious Diseases
Society of America. Clin. Infect Dis 2014; 58:e1-e34.
Capítulo 2
1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1
Infection with Early Antiretroviral Therapy. N Engl J
Med.2011;365(6):493-505.
2. Rodger A, Phillips A, Lundgren J. Prevention of HIV-1 infection
with antiretroviral therapy.N Engl J Med. 2011 Nov
17;365(20):1934.
3. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R,
Paredes R, Bakowska E, Engsig FN, Phillips A; Mortality in well
controlled HIV in the continuous antiretroviral therapy arms of
the SMART and ESPRIT trials compared with the general
population.INSIGHT SMART, ESPRIT Study Groups. AIDS.
2013 Mar 27;27(6):973-9.
4. Hughes JP 1 , Baeten JM, Lingappa JR, Magaret AS, Wald A, de
Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum
C; Determinants of per-coital-act HIV-1 infectivity among
African HIV-1-serodiscordant couples. J Infect Dis. 2012 Feb
1;205(3):358-65.
5. Partners in Prevention HSV/HIV Transmission Study Team. J
Infect Dis. 2012 Feb 1;205(3):358-65.
6. Gardner EM 1 , McLees MP, Steiner JF, Del Rio C, Burman WJThe
spectrum of engagement in HIV care and its relevance to test-andtreat
strategies for prevention of HIV infection.Clin Infect Dis.
2011 Mar 15;52(6):793-800.
7. Geng EH, Hare CB, Kahn JO, et al. The effect of a "universal
antiretroviral therapy" recommendation on HIV RNA levels
among HIV-infected patients entering care with a CD4 count
greater than 500/muL in a public health setting. Clin Infect Dis.
2012;55(12):1690-1697.
8. Study Group on Death Rates at High CDCiANP, Lodwick RK,
Sabin CA, et al. Death rates in HIV-positive antiretroviral naive
patients with CD4 count greater than 350 cells per microL in
Europe and North America: a pooled cohort observational study.
Lancet. 2010;376(9738):340-345.
9. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral
therapy reduces AIDS progression/death in individuals with acute
opportunistic infections: a multicenter randomized strategy trial.
PLoS One. 2009;4(5):e5575.
10. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes
in antiretroviral therapy (ART)-naive participants and in those
not receiving ART at baseline in the SMART study. J Infect Dis.
2008;197(8):1133-1144.
11. Reekie J, Gatell JM, Yust I, et al. Fatal and nonfatal AIDS and non-
AIDS events in HIV-1-positive individuals with high CD4 cell
counts according to viral load strata. AIDS. 2011;25(18):2259-
2268
12. Smith C. Factors associated with specific causes of death amongst
HIV-positive individuals in the D:A:D Study.
AIDS.2010;24(10):1537-1548.
13. Weber R SC, D:A:D Study Group. Trends over time in underlying
causes of death in the D:A:D study from 1999 to 2011. Program
and abstracts presented at: the XIX International AIDS
Conference; 2012; Washington, DC. Abstract THAB0304
14. Wada N, Jacobson LP, Cohen M, French A, Phair J, Muñoz A.
Cause-specific mortality among HIV-infected individuals, by
CD4(+) cell count at HAART initiation, compared with HIVuninfected
individuals.AIDS. 2014 Jan 14;28(2):257-65
15. Mocroft A 1 , Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O,
Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio
Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer
L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F,
Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de
Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J,
Lundgren JD; The incidence of AIDS-defining illnesses at a
c u r r e n t§ C D 4§ c o u n t§ ]§ 2 0 0§ c e l lµL so in the post-combination
antiretroviral therapy era.Opportunistic Infections Working
Group on behalf of the Collaboration of Observational HIV
Epidemiological Research Europe (COHERE) study in
EuroCOORD. Clin Infect Dis. 2013 Oct;57(7):1038-47.
16. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell
J, et al. Long-term exposure to combination antiretroviral therapy
and risk of death from specific causes: no evidence for any
previously unidentified increased risk due to antiretroviral
therapy; EuroSIDA study group. AIDS. 2012 Jan 28;26(3):315-
23.
17. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral
drugs and the risk of myocardial infarction. N Engl J Med.
2007;356(17):1723-1735
18. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious
diseases other than AIDS. AIDS. 2008;22(18):2409-2418
19. Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC,
Justice AC. Incidence of non-AIDS-defining malignancies in
HIV-infected versus noninfected patients in the HAART era:
impact of immunosuppression. J Acquir Immune Defic Syndr.
2009.
20. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection,
immunodeficiency, viral replication, and the risk of cancer.
Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551-2559
21. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the
incidence and predictors of human immunodeficiency
virusassociated dementia in the era of highly active antiretroviral
therapy. Ann Neurol. 2008;63(2):213-221
22. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous
system antiretroviral penetration on cognitive functioning in the
ALLRT cohort. AIDS. 2011;25(3):357-365.
23. Heaton RK, Clifford DB, Franklin DR, Jr., et al. HIV-associated
neurocognitive disorders persist in the era of potent antiretroviral
therapy: CHARTER Study. Neurology. 2010;75(23):2087-2096.
24. Nogueras M, Navarro G, Anton E, et al. Epidemiological and
clinical features, response to HAART, and survival in HIV
infected patients diagnosed at the age of 50 or more. BMC Infect
Dis. 2006;6:159
25. Althoff KN, Justice AC, Gange SJ, et al. Virologic and
immunologic response to HAART, by age and regimen class.
AIDS. 2010;24(16):2469-2479
26. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-
Infected Adults and Adolescents. Nov 2013. Disponible en
http://aidsinfo.nih.gov/guidelines
27. European Aids Clinical Society. Guidelines for treatment of HIVinfected
adults in Europe. Version 7.0 Oct 2013. Disponbile en
http://www.eacsociety.org/Guidelines.aspx
28. Grupo de Estudio del SIDA-SEIMC. Documento de consenso de
GESIDA/Plan Nacional sobre el Sida respecto al tratamiento
antirretroviral en adultos infectados por el virus de la
inmunodericiencia humana. Enero 2014. Disponible en
http://www.gesida-
seimc.org/contenidos/guiasclinicas/2014/gesida-guiasclinicas-
2014-tar.pdf
29. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P,
et al. Antiretroviral treatment of adult HIV infection: 2012
recommendations of the International Antiviral Society-USA
panel. JAMA 2012;308:387-402
30. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS,
Horberg MA. Primary care guidelines for the management of
persons infected with human immunodeficiency virus: 2013
update by the HIV Medicine Association of the Infectious Diseases
Society of America. Clin Infect Dis 2014; 58:e1-e34.
31. European Aids Clinical Society. Guidelines for treatment of HIVinfected
adults in Europe. Version 7.0 Oct 2013. Disponbile en
http://www.eacsociety.org/Guidelines.aspx
172